PDS Biotechnology Corporation Common Stock PDSB
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-10T22:24:44.748Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-10T22:22:34.47396105Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-10T22:24:43.916198+00:00
PDS Biotechnology Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 1.34 | 236.1% | 41.6% | 1.05 | 205.6% | 12.9% |
| 50Δ | 1.21 | 212.9% | 29.8% | 1.12 | 211.2% | 11.6% |
| 55Δ | 1.08 | 189.6% | 18.0% | 1.19 | 216.8% | 10.2% |
| 60Δ | 1.25 | 222.4% | 8.9% | |||
| 65Δ | 1.32 | 228.1% | 7.5% | |||
| 70Δ | 1.39 | 233.7% | 6.2% | |||
| 75Δ | 1.46 | 239.3% | 4.8% | |||
| 80Δ | 1.95 | 274.9% | 3.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.34
- IV
- 236.1%
- B/E move
- 41.6%
- Pseudo strike
- 1.05
- IV
- 205.6%
- B/E move
- 12.9%
50Δ
- Pseudo strike
- 1.21
- IV
- 212.9%
- B/E move
- 29.8%
- Pseudo strike
- 1.12
- IV
- 211.2%
- B/E move
- 11.6%
55Δ
- Pseudo strike
- 1.08
- IV
- 189.6%
- B/E move
- 18.0%
- Pseudo strike
- 1.19
- IV
- 216.8%
- B/E move
- 10.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.25
- IV
- 222.4%
- B/E move
- 8.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.32
- IV
- 228.1%
- B/E move
- 7.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.39
- IV
- 233.7%
- B/E move
- 6.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.46
- IV
- 239.3%
- B/E move
- 4.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.95
- IV
- 274.9%
- B/E move
- 3.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 257.17% | |
| 178.87% | |
| 214.16% | |
| 258.37% | |
| 304.13% | |
| 367.57% | |
| 357.78% | |
| 312.99% |
Biotechnology
PEPG
PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious neurological and…
More →PGEN
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
More →PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is…
More →PHVS
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the…
More →PLX
Description unavailable
More →PRAX
Description unavailable
More →